230 related articles for article (PubMed ID: 30821019)
1. Pharmacologic effects of naldemedine, a peripherally acting μ-opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation.
Kanemasa T; Koike K; Arai T; Ono H; Horita N; Chiba H; Nakamura A; Morioka Y; Kihara T; Hasegawa M
Neurogastroenterol Motil; 2019 May; 31(5):e13563. PubMed ID: 30821019
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological Profile of Naldemedine, a Peripherally Acting
Kanemasa T; Koike K; Takase K; Arai T; Nakamura A; Morioka Y; Hasegawa M
J Pharmacol Exp Ther; 2020 Jun; 373(3):438-444. PubMed ID: 32169839
[TBL] [Abstract][Full Text] [Related]
3. Preventive effects of naldemedine, peripherally acting μ-opioid receptor antagonist, on morphine-induced nausea and vomiting in ferrets.
Kanemasa T; Matsuzaki T; Koike K; Hasegawa M; Suzuki T
Life Sci; 2020 Sep; 257():118048. PubMed ID: 32622946
[TBL] [Abstract][Full Text] [Related]
4. Naldemedine: Peripherally Acting Opioid Receptor Antagonist for Treating Opioid-induced Adverse Effects.
Inagaki M; Kanemasa T; Yokota T
Curr Top Med Chem; 2020; 20(31):2830-2842. PubMed ID: 32648846
[TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of naldemedine for the treatment of opioid-induced constipation.
Song X; Wang D; Qu X; Dong N; Teng S
Expert Rev Clin Pharmacol; 2019 Feb; 12(2):121-128. PubMed ID: 30652502
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age.
Wild J; Webster L; Yamada T; Hale M
Drugs Aging; 2020 Apr; 37(4):271-279. PubMed ID: 32086791
[TBL] [Abstract][Full Text] [Related]
7. A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.
Webster LR; Yamada T; Arjona Ferreira JC
Pain Med; 2017 Dec; 18(12):2350-2360. PubMed ID: 28371937
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of naldemedine for the treatment of opioid-induced constipation: A meta-analysis.
Esmadi M; Ahmad D; Hewlett A
J Gastrointestin Liver Dis; 2019 Mar; 28(1):41-46. PubMed ID: 30851171
[TBL] [Abstract][Full Text] [Related]
9. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
Hale M; Wild J; Reddy J; Yamada T; Arjona Ferreira JC
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):555-564. PubMed ID: 28576452
[TBL] [Abstract][Full Text] [Related]
10. Naldemedine: A Review in Opioid-Induced Constipation.
Blair HA
Drugs; 2019 Jul; 79(11):1241-1247. PubMed ID: 31267482
[TBL] [Abstract][Full Text] [Related]
11. Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study.
Webster LR; Nalamachu S; Morlion B; Reddy J; Baba Y; Yamada T; Arjona Ferreira JC
Pain; 2018 May; 159(5):987-994. PubMed ID: 29419653
[TBL] [Abstract][Full Text] [Related]
12. Naldemedine for the Use of Management of Opioid Induced Constipation.
Urits I; Patel A; Kiernan HC; Clay CJ; Monteferrante N; Jung JW; Berger AA; Kassem H; Hasoon J; Kaye AD; Kaye AM; Viswanath O
Psychopharmacol Bull; 2020 Jul; 50(3):97-118. PubMed ID: 32733114
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological profile of TAN-452, a novel peripherally acting opioid receptor antagonist for the treatment of opioid-induced bowel syndromes.
Suzuki T; Sawada T; Kawai K; Ishihara Y
Life Sci; 2018 Dec; 215():246-252. PubMed ID: 30036489
[TBL] [Abstract][Full Text] [Related]
14. Differences in the morphine-induced inhibition of small and large intestinal transit: Involvement of central and peripheral μ-opioid receptors in mice.
Matsumoto K; Umemoto H; Mori T; Akatsu R; Saito S; Tashima K; Shibasaki M; Kato S; Suzuki T; Horie S
Eur J Pharmacol; 2016 Jan; 771():220-8. PubMed ID: 26712376
[TBL] [Abstract][Full Text] [Related]
15. Onset of action of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: results from 2 randomized, placebo-controlled, phase 3 trials.
Wild J; Yamada T; Arjona Ferreira JC; Hale M
Pain; 2019 Oct; 160(10):2358-2364. PubMed ID: 31145214
[TBL] [Abstract][Full Text] [Related]
16. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.
Katakami N; Harada T; Murata T; Shinozaki K; Tsutsumi M; Yokota T; Arai M; Tada Y; Narabayashi M; Boku N
J Clin Oncol; 2017 Dec; 35(34):3859-3866. PubMed ID: 28968171
[TBL] [Abstract][Full Text] [Related]
17. A Retrospective Study of the Efficacy and Safety of Naldemedine for Treatment of Opioid-Induced Constipation in Patients with Hepatobiliary Pancreatic Cancer.
Kamiya T; Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Koizuka S; Saito T; Obayashi K; Kaira K; Minato K
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984494
[No Abstract] [Full Text] [Related]
18. Some pharmacological properties of a newly synthesized 3-acetoxy-6 beta-acetylthio-10-oxo-N-cyclopropylmethyl-dihydronormorphine (KT-95).
Hosoki R; Niizawa S; Koike K; Sagara T; Kanematsu K; Takayanagi I
Arch Int Pharmacodyn Ther; 1996; 331(2):136-52. PubMed ID: 8937625
[TBL] [Abstract][Full Text] [Related]
19. Involvement of the Peripheral μ-Opioid Receptor in Tramadol-Induced Constipation in Rodents.
Yasufuku K; Koike K; Kobayashi M; Chiba H; Kitaura M; Takenouchi S; Hasegawa M; Morioka Y; Mishima H; Suzuki T; Fujita M
Biol Pharm Bull; 2021; 44(11):1746-1751. PubMed ID: 34719650
[TBL] [Abstract][Full Text] [Related]
20. Prevention and management of diarrhea associated with naldemedine among patients receiving opioids: a retrospective cohort study.
Takagi Y; Osawa G; Kato Y; Ikezawa E; Kobayashi C; Aruga E
BMC Gastroenterol; 2020 Jan; 20(1):25. PubMed ID: 32005157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
